Exploring Functional Paralysis With Advanced Magnetic Resonance Modalities

Sponsor
Swiss Paraplegic Centre Nottwil (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05139732
Collaborator
(none)
75
27

Study Details

Study Description

Brief Summary

In functional neurological disorder (FND), neurological symptoms are present, such as paralysis, weakness and disturbed sensation of limbs, although clinically no abnormalities can be found. It is a poorly understood disorder with uncertain diagnosis, treatment and prognosis. In this study, the subtype functional paralysis is investigated with advanced neuroimaging techniques that go beyond standard clinical examinations. In previous research on FND, healthy volunteers have generally been used as a control group. However, since people with functional paralysis have similar symptoms to people with spinal cord injuries (SCI), it is intended to compare the three groups to find similarities and differences. With the proposed methods, the goal is to gain a detailed understanding of FND regarding nerve cell metabolism, diffusion pathways and neuronal networks involved in cognitive processes such as motor inhibition (reaction or no reaction depending on situation). Neurophysiological data, clinical assessments and questionnaires are carried out in addition to Magnetic Resonance Imaging (MRI).

The aim is to enrol 75 participants in this study, i.e. 25 people with FND, 25 people with SCI and 25 healthy control subjects.

The overall goal of the study is to find markers for FND for use in future studies to improve diagnosis and individualise therapy recommendation for both people with SCI and people with FND. Therefore, this study is a relevant step to understand FND and to diagnose this specific disease using objective MRI based diagnostic tools.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Magnetic Resonance Imaging (MRI)

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
75 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Exploring Functional Paralysis With Advanced Magnetic Resonance Modalities
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
control

Healthy participants

Diagnostic Test: Magnetic Resonance Imaging (MRI)
In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
Other Names:
  • Functional Magnetic Resonance Imaging (fMRI)
  • In-vivo Magnetic Resonance Spectroscopy (MRS)
  • Diffusion Tensor Imaging (DTI)
  • Diffusion Weighted Imaging (DWI)
  • Functional Neurological Disorder (FND)

    People with the subtype functional paralysis

    Diagnostic Test: Magnetic Resonance Imaging (MRI)
    In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
    Other Names:
  • Functional Magnetic Resonance Imaging (fMRI)
  • In-vivo Magnetic Resonance Spectroscopy (MRS)
  • Diffusion Tensor Imaging (DTI)
  • Diffusion Weighted Imaging (DWI)
  • Spinal Cord Injury (SCI)

    Incomplete and complete paralysis with the ability to hold a pen

    Diagnostic Test: Magnetic Resonance Imaging (MRI)
    In order to investigate the metabolic profile, magnetic resonance spectroscopy (MRS) will be applied. Functional MRI (fMRI) allows to indirectly track cell activation measuring the blood-level dependent signal changes followed spontaneously (in resting state) or evoked by a task. Diffusion weighted imaging (DWI) is based on the differences in motion of the water molecules given by the underlying microarchitecture of the nervous tissue. Diffusion tensor imaging (DTI) allows visualisation of the nerve bundles and alterations thereof. Thus, microstructural alterations can be measured.
    Other Names:
  • Functional Magnetic Resonance Imaging (fMRI)
  • In-vivo Magnetic Resonance Spectroscopy (MRS)
  • Diffusion Tensor Imaging (DTI)
  • Diffusion Weighted Imaging (DWI)
  • Outcome Measures

    Primary Outcome Measures

    1. Nerve Cell Metabolism [day 1]

      With MRS metabolites are examined specific for cell integrity (N-acetyl-aspartate), cell energy (creatine, lactate), and neurotransmitter (choline, glutamate and glutamine).

    2. Brain Functional Connectivity [day 1]

      With fMRI in rest and task condition, the functional connectivity (FC) is examined. With that the functionally integrated relationship between spatially separated brain regions are investigated.

    3. Fiber tracts in three dimensional mapping [day 1]

      DWI provides quantitative evaluations by measuring the apparent diffusion coefficient (ADC) and fractional anisotropy (FA), which are scalars of isotropic and anisotropic diffusion. Diffusion tensor imaging (DTI) analyses the three-dimensional shape of the diffusion, also known as diffusion tensor. So, it is used to characterize the magnitude, the degree of anisotropy, and the orientation of directional diffusion of white matter.

    Secondary Outcome Measures

    1. Satisfaction with Life Scale questionnaire [day 1]

      Likert Scale of 1 (strong disagreement) -7 (strong agreement); 5 Questions in total

    2. Hospital Anxiety and Depression Scale questionnaire [day 1]

      Likert Scale of 1 (strong disagreement) -4 (strong agreement); 14 Questions in total

    3. Numerical Rating Scale (NRS) questionnaire [day 1]

      Rating the pain on a likert scale of 0 (no pain) -10 (insupportable pain)

    4. Sensibility testing according to International Standards for Neurological Classification of SCI (ISNCSCI) [day 1]

      A key point in each of the 28 dermatomes is tested bilaterally using light touch and pin-prick (sharp-dull discrimination). A three-point scale is used for scoring: 0 = absent = altered (impaired or partial appreciation, including hyperesthesia) = normal or intact (similar as on the cheek) not testable

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age between 18-65
    Exclusion Criteria:
    • Contraindication for magnetic resonance examinations (e.g. cardiac pacemaker, pregnancy, etc.)

    • history of mental or neurological illness (addiction, central nervous system tumour and severe craniocerebral trauma)

    • unable to hold a pen due to paralysis

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Swiss Paraplegic Centre Nottwil

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Swiss Paraplegic Centre Nottwil
    ClinicalTrials.gov Identifier:
    NCT05139732
    Other Study ID Numbers:
    • 2021-10
    First Posted:
    Dec 1, 2021
    Last Update Posted:
    Aug 9, 2022
    Last Verified:
    Aug 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 9, 2022